Skip to main content
. 2021 May 11;13(5):696. doi: 10.3390/pharmaceutics13050696

Figure 4.

Figure 4

Uptake of FITC-labeled nioplexes in hUSC cells. Lipofectamine was added at a mass ratio of 2:1 and GPxT-CQ 5:1 (w/w). Upper panel: percentage of FITC-positive cells and viability. Data represent the mean ± SD (n = 3). Lower panels: fluorescence micrographs of hUSC cells at 4 h of incubation with FITC-labeled nioplexes (Green). (A) Uptake of GPxT-CQ at a lipid/DNA ratio of 5:1 (w/w). 1.25 μg of DNA and 6.25 μg of GPxT-CQ cationic niosome were added to each well; (B) uptake with Lipofectamine at a lipid/DNA ratio of 2:1 (w/w) used as a positive control. 1.25 μg of the plasmid and 2.5 μg lipofectamine were used. Scale bar: 100 μm.